Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn(R) in the Topical Treatment of Mild to Moderate Acne

Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn(R) in
the Topical Treatment of Mild to Moderate Acne

PETALUMA, Calif., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences,
Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and
markets prescription and non-prescription products in 31 countries, today
announced receipt of the European CE Mark for the Microcyn®-based GramaDerm®
Solution and GramaDerm® Hydrogel. Both products are intended for use in the
topical treatment of mild to moderate acne and are designed to complement
other acne treatments.

The new CE Mark was issued by the European notified body, EMKI. The CE Mark is
an indication that a medical device complies with the essential requirements
of the medical devices directive (93/42/EEC) and that the device has been
subjected to conformity assessment procedures. Receipt of the CE Mark will
allow Oculus to market and sell the Microcyn-based GramaDerm Solution and
GramaDerm Hydrogel in EU member countries that have adopted the medical
devices directive without being subject to additional national regulations
with regard to demonstration of performance and safety, although certain EU
member countries may request or require additional performance and/or safety
data from time to time, on a case-by case basis.

"Securing the CE Mark for our acne products is just the beginning of Oculus'
multiple product development initiatives in our continuing European growth
strategy," said Bruce Thornton, Oculus executive vice president of
international operations. "With CE Mark approval, our EU partnering process
has picked up considerably. In addition, we anticipate announcing regulatory
approvals and commercialization ofother Microcyn-based products, including
those for new oral and advanced wound careindications, over the next few

While a new drug application for Microcyn acne formulation has not yet been
filed in the United States, a number of U.S. dermatologists have been using
the Microcyn-based atopic dermatitis hydrogel since its introduction in early
2012.As permitted by law, some of these physicians have clinically evaluated
the impact of Microcyn in the management of a wide range of dermatological
afflictions including acne.

"We've been successfully using a Microcyn-based hydrogel in my clinic for two
years," said Dr. Rebecca Smith, a dermatologistat Fort Mill Dermatology in
South Carolina. "I have seen promising secondary benefits of Microcyn in
thereduction of inflammation and severity of acne outbreaks. Inlight of the
European directive to reduce the use of topical antibiotics to
minimizeresistance concerns, European dermatologists will be delighted with
the news regardingGramaDerm's approval. We look forward to a similar product
approval in the US in the future."

In a study published in the Journal of Dermatological Treatment (April 2009)
by Tirado-Sánchez, A. "Efficacy and Tolerance of superoxidized solution in the
treatment of mild to moderate inflammatory acne," the Microcyn Technology,
upon which the GramaDerm HydroGel is based, outperformed benzyl peroxide (a
standard ingredient in many acne treatments) in the reduction of inflammatory
lesions as a monotherapy associated with the treatment of acne.At the end of
the 12-week study period, the percentage reduction in the number of
inflammatory lesions from the initial baseline was 65% in the Microcyn arm
versus 54% in the benzyl peroxide arm.The Microcyn product outperformed the
benzyl peroxide, the general standard of care, but the difference was not
statistically significant.However, the Microcyn technology has not, thus far,
demonstrated any bacterial resistance and it tends to have an impeccable
safety profile.

Global Acne Market

In a 2010 report issued by Research and Markets, it was indicated that the
global acne market was worth $2.8 billion in 2009 and is estimated to reach
revenues of $3.02 billion by 2016 at a Compound Annual Growth Rate (CAGR) of
0.7%. The current market has several products which act on acne by targeting
different etiologic factors involved in the development of acne. The acne
therapeutics market is witnessing a shift towards combination products, using
two or more effective acne treatments at one time. 

The acne market is primarily genericised and is moderately served by the
currently marketed drugs. The majority of the pipeline products of large
pharmaceutical companies also consist of combination products with very few
first-in-class molecules. With emerging me-too combination products in the
pipeline that are not significantly different from the current monotherapies,
the acne market awaits a blockbuster advance. Increases in the population in
general and an increase in the prescription rate are estimated to sustain the
acne market in the future.

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs,
manufactures and marketsprescription and non-prescription products in 31
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health; addressing the unmet medical needs of these markets—while raising the
standard ofpatient care and lowering overall healthcare costs. The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the commercial and technology progress and futurefinancial performance
of Oculus Innovative Sciences, Inc. and its subsidiaries (the "Company").
These forward-looking statements are identified by the use of words such as
"anticipates,""believes," "expects," and "intends,"among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2013. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn® Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105
Press spacebar to pause and continue. Press esc to stop.